江浙产蝮蛇毒提取的抗凝成份激活人血浆蛋白C的作用（摘要）

江浙产蝮蛇毒提取的抗凝成份激活人血浆蛋白Ｃ的作用（摘要）瞿国伟,顾肃敏,黄美华,任彤,邵慧珍１．浙江医科大学２．上海市瑞金医院本文从江浙产蝮蛇粗毒中提取到的抗凝成份（ＳＶＰＡ）,具有激活人血浆蛋白Ｃ活性,利用被激活的蛋白Ｃ特异性地分解生色底物而生成颜...     

人红细胞膜和血浆游离脂肪酸成分分析及其对膜微粘度的影响

采用高效液相色谱（ＨＰＬＣ）和荧光偏振技术测定了４２例正常人红细胞膜和血浆游离脂肪酸（ＦＦＡ）及膜微粘度,并探讨了膜脂肪酸和血浆ＦＦＡ构成与膜微粘度之间的关系。结果表明：正常人红细胞膜主要由廿二碳六烯酸（Ｃ２２∶６）、花生四烯酸（Ｃ２０∶４）、亚油酸（Ｃ１８∶２）、软脂酸（Ｃ１６∶０）、油酸（Ｃ１８∶１）和硬脂酸（Ｃ１８∶０）等六种脂肪酸组成。血浆ＦＦＡ构成与膜脂肪酸相似,但不含Ｃ２２∶６而含十四烷酸（Ｃ１４∶０）。红细胞膜各脂肪酸含量大多与其血浆浓度呈明显正相关。红细胞膜微粘度与膜软脂酸和硬脂酸呈明显正相关,与膜廿二碳六烯酸和花生四烯酸呈明显负相关。提示红细胞膜脂肪酸组成受血浆ＦＦＡ成分影响;而红细胞膜脂肪酸成分对膜微粘度亦有重要影响     

实验性肾功能衰竭大鼠血浆中分子物质总量和自由基的变化研究

用腺嘌呤复制动物性慢性肾功能衰竭（ＣＲＦ）模型。观察大鼠血浆血尿素氮（ＢｕＮ）、血肌酐（Ｃｒ）、血红蛋白（Ｈｂ）、超氧化物歧化酶（ＳＯＤ）和中分子物质（ＭＭＳ）总量的变化。结果表明,ＣＲＦ大鼠血浆ＢｕＮ、Ｃｒ和ＭＭＳ总量明显升高（Ｐ〈０．０１）、Ｈｂ和ＳＯＤ含量显著降低（Ｐ〈０．０１）。提示ＣＲＦ大鼠ＭＭＳ总量升高、ＳＯＤ活性降低。     

关于血清 Cu,Zn及 CuZn-SOD 与恶性肿瘤关系的探讨

本文用原子吸收光度法,Ｏｙａｎｇｕｉ法及ＡｄａｃｈｉＹ法分别测定了正常人与五种肿瘤患者血清Ｃｕ,Ｚｎ含量,铜锌超氧化物歧化酶（ＣｕＺｎ－ＳＯＤ）的活性以及谷胱甘肽硫转移酶（ＧＳＴ）的活性。结果表明：恶性肿瘤患者血清中铜含量升高,锌含量降低,ＣｕＺｎ－ＳＯＤ活性降低,而ＧＳＴ活性在正常人与肿瘤患者间无显著差异（Ｐ＞０．０５）。提示人血清中高铜,低锌,高铜／锌比值,以及ＣｕＺｎ－ＳＯＤ活性降低与恶性肿瘤的发生有关。     

几种扩血管多肽对bFGF促血管平滑肌细胞增殖作用的影响

目的和方法：研究肾上腺髓质素（Ａｄｍ）、降钙素基因相关肽（ＣＧＲＰ）及Ｃ－型心房利太（ＣＮＰ）对碱性成纤维细胞生长因子（ｂＦＧＦ）促血管平滑细胞（ＶＳＭＣ）增殖作用的影响及其机制。结果：孵育２４ｈ后,ｂＦＧＦ刺激ＶＳＭＣ增殖较对照组增加２．１倍（Ｐ〈０．０１）,细胞内蛋白磷酸化程度增加１．４倍（Ｐ〈０．０１）,ＰＫＣ及ＭＡＰＫ活性分别增加１．５和２．５倍（Ｐ〈０．０１０;Ａｄｍ．ＣＧＲＰｔ ＣＮＰ     

几种氨基酸─铜（Ⅱ）配合物的超氧化物歧化酶活性

用四氮唑蓝光化学还原法对所合成的ＫＣｕ（ＩＤＡ）（Ｓｅｒ）·２Ｈ２Ｏ、ＫＣｕ（ＩＤＡ）（Ａｌａ）·Ｈ２Ｏ、Ｃｕ（ＩＤＡ）（ｅｎ）、ＫＣｕ（ＩＤＡ）（Ｇｌｙ）·Ｈ２Ｏ和Ｃｕ（ＩＤＡ）·２Ｈ２Ｏ（ＩＤＡ＝Ｎ（羧基甲基）－甘氨酸,Ｓｅｒ＝丝氨酸,Ａｌａ＝丙氨酸,ｅｎ＝乙二胺,Ｇｌｙ＝甘氨酸）等５种氨基酸─铜（Ⅱ）配合物进行了活性测定,发现它们均具有天然超氧化物歧化酶活性,其活性依次为０．３４、０．４５、０．５０、０．５４、０．７２Ｃｕμｍｏｌ·Ｌ－１。     

DIDS和ConA对带3蛋白转运活性及结构的影响

测定了伴刀豆球蛋白（ＣｏｎｃａｎａｖａｌｉｎＡ）和ＤＩＤＳ对人红细胞带３蛋白活性及结构的影响。（１）ＣｏｎＡ使带３转运速度常数Ｋ显著增加。ＣｏｎＡ浓度达到０．０５ｍｇ／ｍｌ时,Ｋ值增加３４．４％。ＤＩＤＳ对带３活性有明显的抑制作用。（２）荧光探针ＤＰＨ,３ＡＳ,９ＡＳ,１６ＡＰ分别测定ＣｏｎＡ和ＤＩＤＳ与带３结合后膜流动性的变化。ＣｏｎＡ能明显增加膜脂的流动性,而ＤＩＤＳ则降低膜脂流动性。（３）差示扫描量热法（ＤＳＣ）测定带３蛋白变性性质,发现ＣｏｎＡ使红细胞膜上带３蛋白变性峰出现温度从６９．２５°Ｃ减小到６６．２５°Ｃ,而ＤＩＤＳ则使之增至７９．５°Ｃ。     

大鼠耐力运动后血浆血管紧张素Ⅱ与尿蛋白组分排泄的相关性研究

本实验测定了大鼠长时间游泳后即刻及恢复中尿中总蛋白（ＴＰ）、白蛋白（Ａｌｂ）、β微球蛋白（β＿２－ｍＧ）排泄率及血浆血管紧张素Ⅱ（ＡⅡ）活性,分析了ＡⅡ与尿蛋白组分排泄率的相关性。结果表明：ＡⅡ活性与Ａｌｂ排泄率相关性较高（ｒ＝０．６６,Ｐ＜０．０５）,ＡⅡ活性与ＴＰ、β＿２－ｍＧ排泄率相关性较低（ｒ＝０．４２,Ｐ＞０．０５;ｒ＝０．３４,Ｐ＞０．０５）。提示ＡⅡ活性在运动后尿蛋白产生机制中与大分子量的Ａｌｂ排泄有较直接关系,而与ＴＰ及小分子量的β＿２－ｍＧ排泄无明显直接关系。     

溶血磷脂酸对家猫心肌细胞蛋白激酶C分布的影响

本文观察了溶血磷脂酸（ＬＰＡ）对心肌细胞内蛋白激酶Ｃ（ＰＫＣ）分布的影响。在离体家猫心脏灌流ＬＰＡ（１０－８ｍｏｌ／Ｌ）后差速离心分别制备心肌细胞胞浆、核及肌膜,测定各部分ＰＫＣ活性。结果显示：与对照组比较,ＬＰＡ组心肌总ＰＫＣ活性增加９．８％（Ｐ＜０．０５）,但胞浆ＰＫＣ活性降低１０．３％（Ｐ＜０．０５）,膜与核的活性分别增加３８．８％和７７．６％（Ｐ＜０．０１）。结论：ＬＰＡ刺激心肌细胞ＰＫＣ活性增强,并可能使ＰＫＣ从胞浆向胞核和肌膜部分转移     

兴奋下丘脑弓状核神经元降低大鼠血浆唾液酸水平的作用

实验采用下丘脑弓状核（ＡＲＣ）区微量注射和紫外分光光度测定法,研究ＡＲＣ区注射不同浓度谷氨酸钠（Ｇｌｕ）对大鼠血浆唾液酸（ＳＡ）水平的影响。结果表明：（１）ＡＲＣ区注射Ｇｌｕ后,血浆ＳＡ水平较对照组明显降低（Ｐ〈０．０１）,而且随Ｇｌｕ浓度的增加,血浆ＳＡ水平降低所需的时间逐渐缩短;（２）侧脑室注射阿朴吗啡后,ＡＲＣ区注射Ｇｌｕ,血浆ＳＡ水平明显降低（Ｐ〈０．０１）,而且降低发生时间较对照组提前：     

Validation of a simple liquid chromatography assay for creatine suitable for pharmacokinetic applications,determination of plasma protein binding and verification of percent labeled claim of various creatine products

Creatine has been quantified in various tissues by a range of methodologies. This paper reports on the development and validation of a simplified HPLC assay to determine plasma creatine, plasma protein binding of creatine, creatine in microdialysate and creatine in over-the-counter products. An isocratic, reversed-phase (C(18)) HPLC assay, using potassium phosphate monobasic (pH 4) as a mobile phase, was validated in human plasma and microdialysis perfusion fluid (normal saline). The lower limit of quantification for the assay was 1 mg l(-1) in saline and 5 mg l(-1) in plasma. The RSD was below 6% and accuracy was below 12% in both matrices. Protein binding in human plasma was found to be negligible (<10%). Over-the-counter creatine monohydrate products tested contained 100% creatine monohydrate. This assay was found to be suitable for pharmacokinetic studies and the assessment of plasma creatine and skeletal muscle microdialysate.     

Competitive protein binding assay for activin A/EDF using follistatin determination of activin levels in human plasma.

A sensitive and specific protein binding assay for activin A/EDF (activin) was developed using follistatin as a binding protein and [125I] labelled activin as a tracer. As 50% acetonitrile (CH3CN) separated free and follistatin-bound activin, plasma pretreated with an equal volume of CH3CN was used as the assay sample and B/F separation was also done with 50% CH3CN. The recovery of the assay was 85.0% and its sensitivity was 0.5 ng/ml. Crossreactivity with inhibin A was 1.8%. The mean plasma level of follistatin-free activin in normal subjects was 1.3 +/- 0.7%. (M +/- SD) ng/ml. Plasma free activin levels were generally elevated in patients with chronic renal failure or hematological diseases associated with anemia.     

A fluorescence-based,high-performance liquid chromatographic assay to determine acid sphingomyelinase activity and diagnose types A and B Niemann-Pick disease

Acid sphingomyelinase (ASM; sphingomyelin phosphodiesterase, EC 3.1.4.12) is the lysosomal enzyme that hydrolyzes sphingomyelin (SPM) to phosphorylcholine and ceramide. An inherited deficiency of ASM activity results in Types A and B Niemann-Pick disease (NPD). In this study we report a new assay method to detect ASM activity and diagnose NPD using the fluorescent substrate BODIPY C12-SPM and reverse-phase high-performance liquid chromatography (HPLC). The reaction product, BODIPY C12-ceramide (B12Cer), could be clearly and efficiently separated from the substrate within 4 min using a reverse-phase column (Aquasil C18, Keystone Scientific). Femtomole quantities of B12Cer could be detected in as little as 1.0 micro l of human plasma, providing a sensitive measure of ASM activity. The mean ASM activity in human plasma from NPD patients (36 pmol/ml/h) was only 2.7% of that in normal plasma (1334 pmol/ml/h), confirming the specificity and diagnostic value of this new assay method. Importantly, the mean ASM activity in human plasma from NPD carriers (258.3 pmol/ml/h) also was significantly reduced (19.5% of normal). The ranges of ASM plasma activities in NPD patients (N=19), NPD carriers (N=11), and normal subjects (N=15) were 2.5-97.3, 108-551, and 1030-2124 pmol/ml/h, respectively. Based on these results, we suggest that this fluorescence-based HPLC assay method is a reliable, rapid, and highly sensitive technique to determine ASM activity and that plasma is a very reliable and simple source for the accurate diagnosis of NPD patients and carriers based on ASM activity.     

Rapid and simple micro-determination of carvedilol in rat plasma by high-performance liquid chromatography

We studied the use of high-performance liquid chromatography (HPLC) with spectrofluorometric detection, using a solid-phase extraction for a simple, rapid and sensitive determination of plasma carvedilol levels in rats. Extracted aliquots were analyzed by HPLC, using a reversed-phase octadecyl silica column. The analytical mean recovery of carvedilol added to the blank plasma was 94.2%. The detection limit was 3.6 ng/ml in the plasma. The reproducibilities (C.V.) were 2.7–7.5% for the within-day assay, and 2.6–7.4% for the between-day assay, indicating that the method was effective for the determination of carvedilol plasma levels.     

Determination of rimantadine in rat plasma by liquid chromatography/electrospray mass spectrometry and its application in a pharmacokinetic study

A rapid and sensitive liquid chromatography/mass spectrometry (LC/MS) method was developed and validated for the determination of rimantadine in rat plasma. Rimantadine was extracted by protein precipitation with methanol, and the chromatographic separation was performed on a C(18) column. The total analytical run time was relatively short (4.6 min), and the limit of assay quantification (LLOQ) was 2 ng/mL using 50 microL of rat plasma. Rimantadine and the internal standard (amantadine) were monitored in selected ion monitoring (SIM) mode at m/z 180.2 and 152.1, respectively. The standard curve was linear over a concentration range from 2 to 750 ng/mL, and the correlation coefficients were greater than 0.999. The mean intra- and inter-day assay accuracy ranged from 100.1-105.0% to 100.3-104.0%, respectively, and the mean intra- and inter-day precision was between 1.3-2.3% and 1.8-3.0%, respectively. The developed assay method was successfully applied to a pharmacokinetic study in rats after oral administration of rimantadine hydrochloride at the dose of 20 mg/kg.     

A radioimmunoassay for plasma dehydroepiandrosterone sulphate incorporating placental steroid sulphatase as a hydrolysing reagent

We describe a method for the measurement of plasma dehydroepiandrosterone sulphate (DHAS) which incorporates a Triton X-100 solubilised preparation of human placental steroid sulphatase as a hydrolysing agent and a direct radioimmunoassay of liberated DHA using a specific antiserum. The hydrolysis procedure is carried out at 50 degrees C for 1 h and an assay run can be completed in 4 h. As determined by the method, plasma concentrations of DHAS in 32 normal adult men (ages 23-58 yr) had a mean value +/- SD of 5.5 +/- 1.89 mumol/l. For 30 normal adult cyclic women (ages 22-35 yr) the mean plasma concentration of DHAS +/- SD was 3.1 +/- 1.35 mumol/l which was significantly lower (P less than 0.01) than found for men. Plasma DHAS concentration were also measured in 50 hirsute female patients. The mean value +/- SD was 5.03 +/- 2.52 mumol/l which was significantly higher (P less than 0.01) than the value for the normal female group. Some 42% of the hirsute patients had DHAS concentrations above the upper 95% probability limit of the normal range for premenopausal women.     

Simple determination of terbutaline in dog plasma by column-switching liquid chromatography

Terbutaline is a beta-adrenergic receptor antagonist that acts as a bronchodilator in the treatment of asthma and chronic bronchitis. In the present work, a column-switching high-performance liquid chromatographic method was developed to monitor terbutaline sulphate in dog plasma. The system consists of a C2 pre-column (PC) and a C18 analytical column connected in series via a switching valve. Atenolol was used as the internal standard. Good linearity was achieved in the range of 5-800 ng/ml plasma. The mean intra- and inter-assay variation coefficients for this analysis were 2.3 and 4.7%, respectively. The average recovery for terbutaline was 87.4% from plasma. The mean concentration after three freeze-thaw cycles was 99.4% of the normal value. The analytical sensitivity and accuracy of this assay is adequate for characterisation of the pharmacokinetics of oral administration of terbutaline to dogs and has been successfully used to provide pharmacokinetic data using pulsatile and immediate-release tablets.     

Release of dog polymorphonuclear leukocyte cathepsin G, normally and in endotoxin and pancreatitic shock. Isolation and partial characterization of dog polymorphonuclear leukocyte cathepsin G

Dog polymorphonuclear leukocyte cathepsin G was isolated from a granule extract using a two-step procedure including affinity chromatography on a Trasylol-Sepharose gel and ion-exchange chromatography on a CM 52 column. 22 of the first 24 N-terminal amino acids were determined and showed 83% and 71% identity to those of human and rat cathepsin G, respectively. Total amino-acid composition demonstrated the basic nature of the protein. In an SDS/polyacrylamide-gel electrophoresis the protein showed an Mr of 29,400 compared to the Mr of 26,800 calculated from the total amino-acid composition. The enzyme was shown to form complexes with alpha 1 alpha 2-macroglobulin and alpha 1-proteinase inhibitor. A specific enzyme-linked immunosorbent assay was developed for the determination of cathepsin G/alpha 1-proteinase inhibitor complex in dog plasma and tissue fluids. The mean concentration of cathepsin G in normal dog plasma was determined to be 38 micrograms/l, measured as cathepsin G/alpha 1-proteinase inhibitor complex. When active dog cathepsin G was added to normal dog plasma in vitro, approximately 56% could be measured by the assay. Slow intravenous infusion of a lethal dose of endotoxin in dogs was followed by a marked drop in white blood cell count and thrombocytes and a simultaneous rapid increase in plasma cathepsin G concentration, reaching a maximum level of 150 micrograms/l. Bile-induced experimental pancreatitis in dogs was accompanied by successive increase in cathepsin G levels in plasma as well as in peritoneal exudates, reaching a maximum level of about 300 micrograms/l in plasma and 18 mg/l in the exudates during the late stages of disease.     

Development and validation of a method to determine the unbound paclitaxel fraction in human plasma

Paclitaxel is pharmaceutically formulated in a mixture of Cremophor EL and ethanol (1:1, v/v). The unbound fraction of the anticancer drug paclitaxel in plasma is dependent on both plasma protein binding and entrapment in Cremophor EL micelles. We have developed a simple and reproducible method for the quantification of the unbound paclitaxel fraction in human plasma. Human plasma was spiked with [3H]paclitaxel and [14C]glucose (unbound reference) and incubated at 37 degrees C for 30 min. Plasma ultrafiltrate was prepared by a micropartition system (MPS-1) and collected in a sample cup containing 100 microl of plasma to prevent the loss of paclitaxel due to adsorption. The radionuclides were separated after combustion of the biological samples using a sample oxidizer and the radioactivity was determined by liquid scintillation counting. The unbound fraction of paclitaxel was calculated by dividing the ratios of 3H and 14C in plasma ultrafiltrate and in plasma. The method was thoroughly validated using human plasma spiked with pharmacologically relevant concentrations of paclitaxel (10-1000 ng/ml) and Cremophor EL (0.25-2.0%). The method was precise, with a within-day precision ranging from 3.9 to 11.0% and a between-day precision ranging from 5.8 to 13.1%. In patient plasma with low serum albumin values containing 1% of Cremophor EL, the unbound fraction appeared to be significantly higher than that in plasma with normal albumin values. The determination of the unbound fraction of paclitaxel proved to be stable during a 10-week storage at -20 degrees C. Furthermore, the assay was applicable in patient samples. This assay can be used to determine the unbound fraction of paclitaxel in plasma. Moreover, its design should allow the determination of the unbound concentrations of other hydrophobic drugs.     

Determination of insulin-like growth factor-I in normal subjects and in patients with growth hormone disorders by radioimmunoassay using biosynthetic homologous peptide

A highly sensitive and specific RIA for IGF-I has been developed using recombinant DNA-derived IGF-I of very high purity and specific antiserum to it. This assay system could detect IGF-I at as low concentrations as 20-30 ng/ml. The intra-assay and interassay coefficients of variation at various concentrations of IGF-I were 4.9 to 6.5% and 5.4 to 8.0%, respectively. The recovery rate of pure IGF-I added to plasma was 77.0 +/- 3.7%. The antiserum did not cross-react with porcine insulin, biosynthetic human insulin, hGH, hEGF, the synthetic C-domain of IGF-I or that of IGF-II, but reacted equally with an analog, Thr59-IGF-I. Plasma IGF-I was extracted by the acid-ethanol method before assay to separate IGF-I from its binding protein. When plasma IGF-I was assayed without extraction, the inhibition curves of serial dilution of plasma samples from several individuals were not parallel to the standard curve of IGF-I. The plasma concentration of IGF-I was 147 +/- 49 ng/ml (mean +/- SD) in 156 normal adults aged from 20-59 years. As reported by others, the IGF-I levels were low in cord plasma (41.8 +/- 23.5 ng/ml) and plasma of patients with GH deficiency (64.6 +/- 42.0 ng/ml), while its levels were high in normal children of pubertal ages (12-13 yr, 365 +/- 126 ng/ml) and in patients with active acromegaly (562 +/- 115 ng/ml). This RIA system is a simple and useful method for determining plasma IGF-I in normal and diseased states.